Equivalence of pegfilgrastim and filgrastim in lymphoma patients treated with BEAM followed by autologous stem cell transplantation.
- Samaras P Department of Oncology, University Hospital Zürich, Zürich, Switzerland.
- Buset EM
- Siciliano RD
- Haile SR
- Petrausch U
- Mischo A
- Honegger H
- Pestalozzi BC
- Schanz U
- Stussi G
- Stahel RA
- Knuth A
- Renner C
- Stenner-Liewen F
- 2010-11-17
Published in:
- Oncology. - 2010
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Carmustine
Cytarabine
Drug Administration Schedule
Female
Filgrastim
Granulocyte Colony-Stimulating Factor
Hodgkin Disease
Humans
Length of Stay
Lymphoma, Non-Hodgkin
Male
Melphalan
Middle Aged
Neutropenia
Peripheral Blood Stem Cell Transplantation
Podophyllotoxin
Polyethylene Glycols
Recombinant Proteins
Severity of Illness Index
Thrombocytopenia
Time Factors
Transplantation, Autologous
Treatment Outcome
Young Adult
English
OBJECTIVE
To evaluate the impact of pegfilgrastim on engraftment, hospital stay and resources in patients with Hodgkin's and non-Hodgkin's lymphoma after conditioning with high-dose BEAM followed by autologous peripheral blood stem cell transplantation (APBSCT) compared with filgrastim.
METHODS
We reviewed patient charts and our prospective transplantation database for clinical data from the post-transplant period. An integrated cost analysis, including the use of blood products and length of hospital stay, was also performed.
RESULTS
Fourteen (26%) patients with Hodgkin's lymphoma and 40 (74%) patients with non-Hodgkin's lymphoma were analyzed. Thirty-four (68%) patients received single-dose pegfilgrastim (6 mg), and 20 (32%) patients received daily filgrastim (5 μg/kg) after APBSCT. No differences were observed regarding duration of neutropenia grade 4 (pegfilgrastim median 7 days/filgrastim median 8 days; p = 0.13), thrombocytopenia grade 4 (7/9.5 days, respectively; p = 0.21), fever (4.5/2 days; p = 0.057), intravenous antibiotic treatment (11/10 days; p = 0.75) or length of hospital stay (16.5/16 days; p = 0.27) between the groups. The use of pegfilgrastim resulted in 12% higher treatment-related costs when compared to filgrastim, without reaching statistical significance (p = 0.38).
CONCLUSION
Pegfilgrastim appears to be equivalent to filgrastim after high-dose BEAM followed by APBSCT in the treatment of lymphoma patients.
To evaluate the impact of pegfilgrastim on engraftment, hospital stay and resources in patients with Hodgkin's and non-Hodgkin's lymphoma after conditioning with high-dose BEAM followed by autologous peripheral blood stem cell transplantation (APBSCT) compared with filgrastim.
METHODS
We reviewed patient charts and our prospective transplantation database for clinical data from the post-transplant period. An integrated cost analysis, including the use of blood products and length of hospital stay, was also performed.
RESULTS
Fourteen (26%) patients with Hodgkin's lymphoma and 40 (74%) patients with non-Hodgkin's lymphoma were analyzed. Thirty-four (68%) patients received single-dose pegfilgrastim (6 mg), and 20 (32%) patients received daily filgrastim (5 μg/kg) after APBSCT. No differences were observed regarding duration of neutropenia grade 4 (pegfilgrastim median 7 days/filgrastim median 8 days; p = 0.13), thrombocytopenia grade 4 (7/9.5 days, respectively; p = 0.21), fever (4.5/2 days; p = 0.057), intravenous antibiotic treatment (11/10 days; p = 0.75) or length of hospital stay (16.5/16 days; p = 0.27) between the groups. The use of pegfilgrastim resulted in 12% higher treatment-related costs when compared to filgrastim, without reaching statistical significance (p = 0.38).
CONCLUSION
Pegfilgrastim appears to be equivalent to filgrastim after high-dose BEAM followed by APBSCT in the treatment of lymphoma patients.
- Language
-
- English
- Open access status
- green
- Identifiers
-
- DOI 10.1159/000320604
- PMID 21079406
- Persistent URL
- https://folia.unifr.ch/global/documents/80898
Statistics
Document views: 12
File downloads:
- fulltext.pdf: 0